Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
WIN378 · 2 trials · 2 indications
Clinical chemistry assessments will include serum chemistry (such as sodium, potassium, urea, creatinine) and liver function parameters, including alanine aminotransferase (ALT), aspartate aminotransferase (AST) and bilirubin.
Haematology assessments will include haemoglobin, white blood cell count, differential white blood cell counts and platelet count
Coagulation assessments will include activated partial thromboplastin time, international normalised ratio, prothrombin time and fibrinogen
Urinalysis assessments will include protein, pH, blood, glucose and leucocytes
Electrocardiogram assessments will include evaluation of QT interval corrected using Fridericia's formula (QTcF)
| Arm | Type | Description |
|---|---|---|
| WIN378 Dose 1 | EXPERIMENTAL | WIN378 SC injections will be administered |
| WIN378 Dose 2 | EXPERIMENTAL | WIN378 SC injections will be administered |
| Placebo | EXPERIMENTAL | Placebo SC injections will be administered |
| WIN378 | EXPERIMENTAL | WIN378 SC injections |
| Name | Type | Description |
|---|---|---|
| WIN378 | DRUG | WIN378 is a fully human, long-acting monoclonal antibody that targets the ligand of thymic stromal lymphopoietin (TSLP), blocking its activity and thereby reducing airway inflammation and improving COPD control over an extended dosing interval |
| Placebo | DRUG | Placebo matching WIN378 |
Inclusion Criteria: * Adults aged 40 to 80 years * Post-BD spirometry at screening FEV1/FVC \< 0.70 and FEV1 30-80% predicted * On stable triple inhaled therapy (ICS/LABA/LAMA) for ≥ 3 months * Former smoker (≥ 10 pack-year history) and abstinence from smoking for ≥ 6 months * Elevated eosinophil c...
Top 16 of 17 competitors